baCta closes €7M seed round to accelerate growth
baCta, an emerging biotech startup, has secured a €7 million seed funding round led by venture firms LocalGlobe and Daphni, with additional participation from OVNI Capital. The fresh capital positions the company to scale its technology, expand its team, and push forward its product roadmap.
Strategic backing from leading venture investors
The involvement of LocalGlobe and Daphni underscores growing investor confidence in baCta‘s approach and market potential. Both funds are known for backing high-growth European innovators at the earliest stages, helping them transform into category-defining companies.
By joining the round, OVNI Capital adds further sector expertise and a strong network, which is expected to support baCta in partnerships, hiring, and international expansion. The combined investor group brings experience across biotechnology, deep tech, and data-driven platforms, giving the startup a strategic advantage as it moves from proof-of-concept to commercialization.
Focus on scaling technology and product development
The €7 million seed funding will primarily be used to advance baCta‘s core technology, strengthen its research and development capabilities, and support regulatory and go-to-market activities. The company plans to expand its scientific and engineering teams, invest in new infrastructure, and deepen collaborations with industry and academic partners.
With this round, baCta aims to accelerate the validation of its platform, refine its product offering, and prepare for broader deployment. The startup is positioning itself to address critical challenges in the biotech ecosystem, leveraging data analytics, automation, and advanced laboratory workflows to deliver scalable solutions.
Strengthening position in the European innovation landscape
The seed investment highlights the continued momentum of European biotech innovation and the appetite among investors for startups combining scientific depth with scalable technology platforms. With the backing of prominent funds, baCta is expected to become a key player in its segment, contributing to the region’s competitiveness in life sciences and advanced research technologies.